This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Harrow (HROW) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Harrow (HROW) Stock Jumps 11.4%: Will It Continue to Soar?
by Zacks Equity Research
Harrow (HROW) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Are Options Traders Betting on a Big Move in Harrow Stock?
by Zacks Equity Research
Investors need to pay close attention to HROW stock based on the movements in the options market lately.
Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Harrow (HROW) delivered earnings and revenue surprises of -2,000% and 19.88%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
United Therapeutics (UTHR) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
United Therapeutics (UTHR) delivered earnings and revenue surprises of 5.41% and 9.39%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Harrow (HROW) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Harrow (HROW) delivered earnings and revenue surprises of 127.27% and 1.24%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Implied Volatility Surging for Harrow (HROW) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Harrow (HROW) stock based on the movements in the options market lately.
Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ionis Pharmaceuticals (IONS) delivered earnings and revenue surprises of 41.07% and 65.19%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Harrow (HROW) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Harrow (HROW) delivered earnings and revenue surprises of -140% and 11.42%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Lyra Therapeutics, Inc. (LYRA) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Lyra Therapeutics (LYRA) delivered earnings and revenue surprises of 21.74% and 51.25%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Harrow (HROW) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Harrow (HROW) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Will Harrow (HROW) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Best Momentum Stocks to Buy for November 6th
by Zacks Equity Research
HROW, ORLA and SWDBY made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on November 6, 2024.
New Strong Buy Stocks for November 6th
by Zacks Equity Research
ORLA, SWDBY, SUOPY, HROW and CLPR have been added to the Zacks Rank #1 (Strong Buy) List on November 6, 2024.
Century Therapeutics, Inc. (IPSC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Century Therapeutics (IPSC) delivered earnings and revenue surprises of 19.57% and 69.74%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Harrow (HROW) Upgraded to Strong Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Harrow (HROW) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts Believe Harrow (HROW) Could Rally 25.95%: Here's is How to Trade
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 26% in Harrow (HROW). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
GitLab and Baidu have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
GitLab and Baidu have been highlighted as Zacks Bull and Bear of the Day.
Best Momentum Stocks to Buy for October 24th
by Zacks Equity Research
FOLD, CLPR and HROW made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on October 24, 2024.
New Strong Buy Stocks for October 24th
by Zacks Equity Research
CLPR, HROW, FOLD, GTLB and TCOM have been added to the Zacks Rank #1 (Strong Buy) List on October 24, 2024.
Recent Price Trend in Harrow (HROW) is Your Friend, Here's Why
by Zacks Equity Research
Harrow (HROW) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Harrow (HROW) Surges 8.4%: Is This an Indication of Further Gains?
by Zacks Equity Research
Harrow (HROW) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Harrow (HROW) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Harrow (HROW) delivered earnings and revenue surprises of 48% and 14.40%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Harrow (HROW) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Harrow (HROW) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Harrow (HROW) Soars 12.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Harrow (HROW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.